Valdecoxib has been assigned to a pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. Data from human pregnancy studies are not available. Valdecoxib should only be given during pregnancy when benefit outweighs risk.

The manufacturer recommends that valdecoxib be avoided in late pregnancy (third trimester) due to the risk of premature closure of the ductus arteriosus.

See references

There are no data on the excretion of valdecoxib into human milk. Valdecoxib and its active metabolite are excreted in the milk of lactating rats. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue valdecoxib, taking into account the importance of the drug to the mother.

See references